



Asymmetric Synthesis of Ipatasertib



Synthesis of fragment G:



Significance: Ipatasertib (GDC-0068) is an Akt kinase inhibitor that is of interest for the treatment of cancer. The stereogenic centers in fragment **F** were installed using a nitrilase-catalyzed resolution of nitrile (*rac*)-**A** and a ketoreductase-catalyzed reduction of ketone **D**. For a related large-scale synthesis of Ipatasertib, see: T. Remarchuk et al. *Org. Process Res. Dev.* **2014**, *18*, 1652.

SYNFACTS Contributors: Philip Kocienski
 Synfacts 2017, 13(12), 1229 Published online: 17.11.2017
 DOI: 10.1055/s-0036-1591619; Reg-No.: K05017SF

Comment: The stereogenic center in fragment **L** was installed by asymmetric hydrogenation. Using [Ru(TFA)₂((S)-BINAP)] with catalyst activation by NaBr as an additive, allowed for S/C = 10,000. The optimal ratio to ensure reaction robustness was Ru/NaBr = 1:20 and thus afforded >99% conversion and 98.8:1.2 er.